Skip to Main Content

Paper Details

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.
J Clin Oncol
580
2008
Author NameAffiliation
Chang-Qi ZhuPrincess Margaret Hospital, University Ave
  • 1 - 1

Datasets

Release 1.2